• Aliases: MDX-010; MDX-CTLA-4; MOAB- CTLA-4
    • Recombinant human IgG1 monoclonal antibody, which binds to the CTLA-4
    • FDA approved for unresectable or metastatic melanoma
    • Recommended dose: 3 mg/kg IV Q 3 weeks for four total doses
    • Half-life: 15.4 days
    • Common side effects: Immune-mediated adverse effects (TEN, endocrine disorder, enterocolitis, hepatitis, neuropathy) (black box warning), fatigue, headache, rash/pruritus, nausea/vomiting, diarrhea, abdominal pain
    Other topics in Targeted and Immunotherapy Agents